Drug Combination Details
| General Information of the Combination (ID: C38290) | |||||
|---|---|---|---|---|---|
| Name | Thymoquinone NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NOTCH1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PSMC4 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| In-vivo Model | PANC-1 cells (1*106 cells/50 ll) were injected into the pancreatic parenchyma of female BALB/c nude mice. | |||||
| Experimental
Result(s) |
Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer. | |||||
